Rationale Design and Methods of the Study of Comparison of Canagliflozin vs. Teneligliptin Against Basic Metabolic Risks in Patients with Type 2 Diabetes Mellitus (CANTABILE study): Protocol for a Randomized Parallel-Group Comparison Trial

摘要

Study design. A total of 200 patients with type 2 diabetes mellitus (100 patients/group) will participate in this study. After the confirmation of eligibility by a central managing modality, the enrolled patients will be randomly assigned to canagliflozin or teneligliptin therapy. In the canagliflozin group, 100 mg canagliflozin will be orally administered once per day. In the teneligliptin group, 20 mg Teneligliptin will be orally administered once per day. If necessary, the teneligliptin dose can be increased to up to 40 mg per day